{"organizations": [], "uuid": "d2e060e76a032dc8050db6c28eed4b94912c1d4d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-immunogen-completes-interim-analys/brief-immunogen-completes-interim-analysis-for-forward-i-phase-3-trial-of-mirvetuximab-soravtansine-idUSASC09XU6", "country": "US", "domain_rank": 408, "title": "Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.281, "site_type": "news", "published": "2018-04-27T04:42:00.000+03:00", "replies_count": 0, "uuid": "d2e060e76a032dc8050db6c28eed4b94912c1d4d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-immunogen-completes-interim-analys/brief-immunogen-completes-interim-analysis-for-forward-i-phase-3-trial-of-mirvetuximab-soravtansine-idUSASC09XU6", "ord_in_thread": 0, "title": "Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "immunogen", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "immunogen inc", "sentiment": "negative"}, {"name": "immunogen completes interim analysis for forward", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - ImmunoGen Inc:\n* IMMUNOGEN ANNOUNCES SUCCESSFUL COMPLETION OF INTERIM ANALYSIS FOR FORWARD I PHASE 3 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT OVARIAN CANCER\n* IMMUNOGEN INC - FORWARD I TRIAL HAS COMPLETED FULL ENROLLOMENT; TOP-LINE RESULTS EXPECTED IN FIRST HALF OF 2019 Source text for Eikon:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-27T04:42:00.000+03:00", "crawled": "2018-04-27T16:16:05.016+03:00", "highlightTitle": ""}